Loading...

Home
ETF
MDCX

MDCX

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Technical News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press
Privacy
Terms of Service
Service Terms of Use

Resources

Blog
Tutorial
Help Center
Affiliate Program

Markets

Market Analysis
Crypto
Featured Screeners
AI Earnings Calendar
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

QuantAI Alpha Pick
SwingMax Portfolio
Swing Trading
AI Stock Picker
Whales Auto Tracker
Daytrading Center
Patterns Detection
AI Screener
Financial AI Agent
Backtesting Playground
AI Earnings Prediction
Stock Monitor
Technical Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

MDCX News

Medicus Pharma Reports Positive Clinical Results for D-MNA

4d agoNewsfilter

Medicus Pharma Advances SkinJect Development for Gorlin Syndrome

Apr 27 2026Newsfilter

Highlights from New to The Street Broadcast

Apr 25 2026Yahoo Finance

Medicus Pharma Submits Orphan Drug Designation for SkinJect®

Apr 17 2026Newsfilter

Medicus Pharma Files Application for Orphan Drug Designation with U.S. FDA for Skinject® in Gorlin Syndrome

Apr 17 2026moomoo

Medicus Pharma Presents Phase 1 Data on Teverelix at AACE 2026

Apr 15 2026Newsfilter

Medicus Pharma Submits New Drug Study Protocol to FDA

Apr 06 2026NASDAQ.COM

Medicus Pharma Submits Optimized Phase 2 Study Design for Teverelix

Apr 06 2026Newsfilter

Medicus Pharma Clarifies SKNJCT-003 Clinical Data Results

Apr 01 2026Newsfilter

Medicus Pharma's Phase 2 SkinJect Data Validated by KOL

Mar 30 2026Newsfilter

MEDICUS PHARMA ANNOUNCES KOL ENDORSEMENT OF SKINJECT PHASE 2 RESULTS SHOWING 80% OVERALL RESPONSE RATE

Mar 30 2026moomoo

Medicus Pharma Announces SkinJect Study Progress and Future Plans

Mar 26 2026Newsfilter

Medicus Pharma to Discuss 80% Overall Response Rate in Phase 2 Skinject Study and AI-Driven Drug Development Strategy in Business Update Call

Mar 26 2026moomoo

Medicus Pharma Reports FY Loss of $35.4M Amidst $2.74 EPS

Mar 26 2026seekingalpha

Zevra Therapeutics Reports Strong Q4 Earnings, Shares Surge

Mar 10 2026Benzinga

Medicus Pharma Reports New Data on Skin Cancer Treatment

Mar 09 2026Newsfilter